Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract PO1-26-03: Activity of alpelisib in a panel of breast XPDX models harboring hotspot and uncommon PIK3CA mutations

Cancer Res (2024) 84 (9_Supplement): PO1-26-03.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-26-03

Published: 02 May 2024

View articletitled, Abstract PO1-26-03: Activity of alpelisib in a panel of breast XPDX models harboring hotspot and uncommon PIK3CA mutations

Journal Articles

Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models

Cancer Res (2024) 84 (9_Supplement): PO1-26-02.

https://doi.org/10.1158/1538-7445.SABCS23-PO1-26-02

Published: 02 May 2024

View articletitled, Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models

Journal Articles

Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd)

Maci DeBoer, Albert Paez, Johnnie Flores, Robyn Baeza, Alyssa Simonson, Jim Lund, Kyriakos Papadopoulos, Thomas Gribbin, Amy Lang, Gladys Rodriguez, Lorena Mozas, Lorena Gonzalez, Manish Sharma, Emiliano Calvo, Tatiana Hernandez, Michael J. Wick

Cancer Res (2023) 83 (7_Supplement): 3855.

https://doi.org/10.1158/1538-7445.AM2023-3855

Published: 04 April 2023

View articletitled, Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd)

Journal Articles

Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models

Alyssa Simonson, Johnnie Flores, Morgan Lynch, Emily Carpenter, Justine Hruzek, Jim Lund, Natalia Baños Herraiz, Kyriakos Papadopoulos, Amy Vander Woude, Gladys Rodriguez, Sreenivasa Chandana, Thomas Gribbin, Nehal Lakhani, Tatiana Hernandez, Maria Jose de Miguel, Amy Lang, Michael J. Wick

Cancer Res (2023) 83 (7_Supplement): 3869.

https://doi.org/10.1158/1538-7445.AM2023-3869

Published: 04 April 2023

View articletitled, Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models

Journal Articles

Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

George Plasko, Johnnie Flores, Alyssa Simonson, Peter Forofontov, Ashwin Varma, Amy Lang, Gladys Rodriguez, Kyriakos P. Papadopoulos, Drew Rasco, Amita Patnaik, Bruce Conway, Joe Johnston, Michael Wick

Cancer Res (2023) 83 (5_Supplement): P1-13-03.

https://doi.org/10.1158/1538-7445.SABCS22-P1-13-03

Published: 01 March 2023

View articletitled, Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Journal Articles

Abstract P3-08-05: Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models

Cancer Res (2023) 83 (5_Supplement): P3-08-05.

https://doi.org/10.1158/1538-7445.SABCS22-P3-08-05

Published: 01 March 2023

View articletitled, Abstract P3-08-05: Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models

Journal Articles

Abstract P5-01-11: Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies

April Cabang, Crystal Moreno, Johnnie R Flores, Jenna Boedeker, Alyssa Simonson, Jun Ma, Amy Lang, Gladys Rodriguez, Arthur Rosenthal, Kyriakos Papadopoulos, Amita Patnaik, Drew Rasco, Lon Smith, Murali Beeram, Ronald Drengler, Luis Rodriguez, Steven Abbate, Scott Ulmer, Michael J Wick

Cancer Res (2022) 82 (4_Supplement): P5-01-11.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-11

Published: 15 February 2022

View articletitled, Abstract P5-01-11: Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies

Journal Articles

Abstract P5-01-04: Correlation of HER2 receptor expression and in vivo activity of the HER2-targeting therapies trastuzumab deruxtecan (DS-8201a) and T-DM1 activity in a panel of breast XPDX models

Alyssa Simonson, Peter Forofontov, Johnnie R Flores, Kimberly Hernandez, April Cabang, Amy Lang, Gladys Rodriguez, Kyriakos Papadopoulos, Murali Beeram, Arthur Rosenthal, Brittany DeBerry, Lon Smith, Ronald Drengler, Amita Patnaik, Drew Rasco, Luis Rodriguez, Steven Abbate, Scott Ulmer, Michael Wick

Cancer Res (2022) 82 (4_Supplement): P5-01-04.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-04

Published: 15 February 2022

View articletitled, Abstract P5-01-04: Correlation of HER2 receptor expression and in vivo activity of the HER2-targeting therapies trastuzumab deruxtecan (DS-8201a) and T-DM1 activity in a panel of breast XPDX models

Journal Articles

Abstract P5-01-09: Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Johnnie R Flores, Anna Stackpole, Abimael Garza, Alexandra Ulmer, Alyssa Simonson, Kyriakos Papadopoulos, April Cabang, Jun Ma, Amita Patnaik, Drew Rasco, Amy Lang, Gladys Rodriguez, Murali Beeram, Michael J Wick

Cancer Res (2022) 82 (4_Supplement): P5-01-09.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-09

Published: 15 February 2022

View articletitled, Abstract P5-01-09: Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Journal Articles

Abstract P5-01-06: Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors

Tatiana Hernandez, Dustin Kneifel, Alyssa Simonson, Johnnie R Flores, Sarah Quick, April Cabang, Alexandra Ulmer, Kyriakos Papadopoulos, Amy Lang, Gladys Rodriguez, Murali Beeram, Drew Rasco, Amita Patnaik, Scott Ulmer, Michael J Wick

Cancer Res (2022) 82 (4_Supplement): P5-01-06.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-06

Published: 15 February 2022

View articletitled, Abstract P5-01-06: Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors

Journal Articles

Abstract 1398: Establishment and characterization of a clinically-relevant personalized hormone-dependent breast cancer tumor model.

Michael J. Wick, Teresa L. Vaught, Lizette Gamez, Jennifer Brown, Alyssa Moriarty, Anthony W. Tolcher, Drew W. Rasco, Amita Patnaik, Gladys Rodriguez, Ronald L. Drengler, Kyriakos P. Papadopoulos

Cancer Res (2013) 73 (8_Supplement): 1398.

https://doi.org/10.1158/1538-7445.AM2013-1398

Published: 15 April 2013

View articletitled, Abstract 1398: Establishment and characterization of a clinically-relevant personalized hormone-dependent breast cancer tumor model.

Journal Articles

A Phase I Clinical and Pharmacokinetic Trial of Hepsulfam

Peter M. Ravdin, Kathy A. Havlin, Milton V. Marshall, Thomas D. Brown, James M. Koeller, John G. Kuhn, Gladys Rodriguez, Daniel D. Von Hoff

Cancer Res (1991) 51 (23_Part_1): 6268–6272.

Published: 12 January 1991

View articletitled, A Phase I Clinical and Pharmacokinetic Trial of Hepsulfam

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract PO1-26-03: Activity of alpelisib in a panel of breast XPDX models harboring hotspot and uncommon PIK3CA mutations

Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models

Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd)

Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models

Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Abstract P3-08-05: Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models

Abstract P5-01-11: Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies

Abstract P5-01-04: Correlation of HER2 receptor expression and in vivo activity of the HER2-targeting therapies trastuzumab deruxtecan (DS-8201a) and T-DM1 activity in a panel of breast XPDX models

Abstract P5-01-09: Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Abstract P5-01-06: Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors

Abstract 1398: Establishment and characterization of a clinically-relevant personalized hormone-dependent breast cancer tumor model.

A Phase I Clinical and Pharmacokinetic Trial of Hepsulfam

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only